

## **Pubblicazioni**

- 1) G. Grassi, L. Zentilin, S. Tafuro, S. Diviacco, A. Ventura, A. Falaschi and M. Giacca. A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. **Nucleic Acid Research** 1994 vol 22, No. 21, pp 4547-4549.
- 2) G. Grassi, G. Pozzato, M. Moretti and M. Giacca. Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction. **Journal of Hepatology** 1995, vol 23, pp 403-411.
- 3) L. Zentilin, S. Tafuro, G. Grassi, R. Garcia, A. Ventura, F. Baralle, A. Falaschi and M. Giacca. Functional reconstitution of oxidase activity in X-Linked chronic granulomatous disease by retrovirus-mediated gene transfer. **Experimental Cell Research** 1996, vol 225, pp257-267.
- 4) G. Grassi and J.C. Marini. Ribozymes: Structure, Function and Potential Therapy for Dominant Genetic Disorders. **Annals of Medicine** 1996, vol 28, number 6, pp 499-510
- 5) G. Grassi, A. Forlino and J.C. Marini. Cleavage of collagen RNA transcripts by hammerhead ribozymes *in vitro* is mutation-specific and shows competitive binding effects. **Nucleic Acid Research**, 1997, Vol 25, No.17, pp3451-3458
- 6) Brambilla-S; Bellati-G; Asti-M; Lisa-A; Candusso-ME; D'Amico-M; Grassi-G; Giacca-M; Franchini-A; Bruno-S; Ideo-G; Mondelli-MU; Silini-EM. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. **Hepatology**. 1998 Jun; 27(6): 1678-86
- 7) G. Grassi, A. Kuhn, M. Grassi, J.Platz , G. Bauriedel and R. Kandolf. Selection and characterisation of highly active hammerhead ribozymes targeted against cyclin E and E2F1 full length mRNAs. **Antisense and Nucleic Acid Drug Development**, Volume 11 Number 5, 271-287 (October), 2001
- 8) Gabriele Grassi, Mario Grassi, Anne Kuhn, and Reinhard Kandolf Determination Of Hammerhead Ribozyme Kinetic Constants At High Molar Ratio Ribozyme-Substrate. **Journal of Mathematical Biology**,45, 261-277 (2002).
- 9) G. Grassi, P. Maccaroni R. Meyer H. Kaiser, E. D'Ambrosio, E. Pascale, M. Grassi, A.Kuhn, P. Di Nardo, R. Kandolf and J-H Küpper. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. **Carcinogenesis**, 2003 24: 1625-1635.
- 10) Marcus P.S. Dekens, Cristina Santoriello, Daniela Vallone, Gabriele Grassi, David Whitmore & Nicholas S. Foulkes. Light regulates cell cycle progression in zebrafish via the circadian clock. **Current Biology** Vol. 13, 1–20, December 2, 2003.
- 11) G. Grassi, P. Dawson, R. Kandolf G. Guarnieri, M.Grassi. Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases. **Current Pharmaceutical Biotechnology**. 2004 Aug;5(4):369-86.

- 12) M. Grassi and G. Grassi. Mathematical modeling and controlled drug delivery: matrix systems. **Current Drug Delivery**. 2005, volume 2(1), 97-116
- 13) Gianfranco Guarnieri, Gabriele Grassi, Rocco Barazzoni, Michela Zanetti, and Gianni Biolo. The Impact of Inflammation on Metabolic Regulation in Chronic Kidney Disease: A Review. **Journal of Renal Nutrition**. 2005 Jan;15(1):121-4.
- 14) G. Grassi, A. Schneider, S. Engel, R. Kandolf and A. Kuhn. Hammerhead ribozymes targeted against cyclin E and E2F1 co-operate to down regulate coronary smooth muscle cell proliferation. **Journal of Gene Medicine**, 2005, 7: 1223-1234.
- 15) Gabriele Grassi, Rossella Farra, Paolo Caliceti, Mario Grassi. Temperature-Sensitive Hydrogels: Potential Therapeutic Applications. **American Journal of Drug Delivery**. 2005; 3 (4):239-251
- 16) G. Grassi, H. Köhn, B. Dapas, R. Farra, J. Platz, S. Engel, S. Cjsareck, R. Kandolf C. Teutsch, R. Klima, G. Triolo, and A. Kuhn. Comparison between recombinant baculo and adenoviral-vectors as transfer system in cardiovascular cells. **Archives of Virology**, 2006 151:255-271.
- 17) Gianni Biolo, Antonio Amoroso, Silvana Savoldi, Alessandra Bosutti, Massimiliano Martone, Doroti Pirulli, Francesco Bianco, Sheila Ulivi, Sara Bertok, Mary Artero, Rocco Barazzoni, Michela Zanetti, Gabriele Grassi, Gianfranco Guarnieri, Giovanni Panzetta. Association Of Interferon- $\gamma$  +874a Polymorphism With Reduced Long-Term Inflammatory Response In Hemodialysis Patients. **Nephrology Dialysis Transplantation**. 2006 May;21(5):1317-22.
- 18) B Scaggiante, B Dapas, G Grassi, G Manzini.. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. **FEBS Journal**, 102 (1):19-28, 2006
- 19) Nicola Fiotti, Nicola Altamura, Maurizio Fiscaro, Nicola Carraro, Laura Uxa, Gabriele Grassi, Raffaella Gobbato, Gianfranco Guarnieri, Bernard Timothy Baxter, Carlo Giansante. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. **Atherosclerosis, Thrombosis and Vascular Biology**. 26(6) 1330-6, 2006
- 20) Gabriele Grassi; Andrea Crevatin; Rossella Farra; Gianfranco Guarnieri, Andrea Pancotto, Bernard Rehimers; Romano Lapasin and Mario Grassi. Rheological properties of aqueous pluronic-alginate systems containing liposomes **Journal of Colloid and Interface Science**, 301 (1) 282-90, 2006
- 21) G. Grassi, N. Coceani, R Farra, B. Dapas, G. Racchi, N. Fiotti, A. Pascotto, B. Rehimers, G. Guarnieri, M. Grassi. Propaedeutic study for the delivery of nucleic acid based molecules from PLGA microparticles and Stearic acid nanoparticles. **International Journal of Nanomedicine**, 1 (4): 523-533, 2006.
- 22) F. Agostini, B. Dapas, R. Farra, M. Grassi, G. Racchi, K. Klingel, R. Kandolf, O. Heindenreich, A. Mercatanti, G. Rainaldi, N. Altamura, G. Guarnieri, and G. Grassi. Potential applications of small interfering RNA in the cardiovascular field. **Drug of the future**, 31(6): 513-525, 2006.
- 23) M Zanetti, R Barazzoni, A Bosutti, A Stocca , G Grassi and G Guarnieri. Vascular sources of oxidative stress: implications for uremia-related cardiovascular disease. **Journal of Renal Nutrition**, 2007 17 (1): 53-6.

- 24) A Bosutti\*, G Grassi\*, M Zanetti, AAleksova, M Zecchin, G Sinagra, G Biolo and G Guarnirei. \*fist co-authorship. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66 (shca) in pacemaker implanted patients. **Clinical and Experimental Medicine** 7 (1): 16-23, 2007.
- 25) J. Platz, M. Grassi, A. Kuhn, R. Kandolf, G. Racchi, C. Farra. R, Dapas .B, A. Pascotto, C. Giansante N. Fiotti, G. Guarnierei and and G. Grassi. Effects of various promoter derived sequences on the cleavage kinetic of an hammerhead ribozyme directed against cyclin E1 mRNA. **Drug Metabolism letter** 1, 218-225, 2007.
- 26) Alessandra Bosutti, Bruna Scaggiante, Gabriele Grassi, Gianfranco, Guarnieri, and Gianni Biolo. Overexpression of the elongation factor 1a1 gene directly correlates with the rate of proteolysis and the pro-apoptotic p66 (shca) gene transcription in skeletal muscle of traumatized patients. **Metabolism, Clinical and Experimental** 2007, 56: 1629-34.
- 27) Grassi G, Scaggiante B, Farra R, Dapas B, Agostini F, Baiz D, Rosso N, and Tiribelli C. The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. **Biochimie** 2007, 89, 1544-1522.
- 28) Alessandra Bosutti\*; Gabriele Grassi\*; Nicola Fiotti, Gianfranco Guarnirei. Decreased il-10 mRNA expression in patients with advanced renal failure undergoing conservative treatment. **Cytokines**, 40: 71-74, 2007 . \*fist co-authorship
- 29) Grassi G, Farra R, Noro E, Voinovich D, Lapasin R, Dapas B, Alpar O, Zennaro C, Carraro M, Giansante C, Guarnieri G, Pascotto A, Rehimers B, Grassi M. Characterization of nucleid acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices. **Journal of Drug Delivery Science and Technology**, 2007 17,5: 325-331.
- 30) C. Lang, M Sauter, G Szalay, G Racchi, G Grassi, G Rainaldi, A Mercatanti, F Lang, R Kandolf, and K Klingel. Connective tissue growth factor: A crucial cytokine mediating cardiac fibrosis in ongoing enterovirus myocarditis. **Journal of Molecular Medicine**. 2008, 86 (1) 49-60.
- 31) M. Zanetti, A. Stocca, B. Dapas, R. Farra, A. Bosutti, R. Barazzoni, C. Giansante, F. Tedesco, L. Cattin, G. Guarnieri and G. Grassi. Inhibitory Effects Of Fenofibrate On Apoptosis And Cell Proliferation In Human Endothelial Cells In High Glucose. **Journal of Molecular Medicine**, 2008, 86 (2) 185-95.
- 32) Preparation of sustained release co-extrudates by hot melt extrusion and evaluation of bioavailability by mathematical modelling. U. Quintavalle, D. Voinovich, B. Perissutti, F. Serdoz, G. Grassi, A. Dal Col, M. Grassi. **European Journal of Pharmaceutical Sciences**, 33, 282-293, 2008.
- 33) Prostate Tumour-Inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection. Bruna Scaggiante, Serena Bonin, Luigi Cristiano, Salvatore Siracusano, Giorgio Stanta, Barbara Dapas, Carlo Giansante, Nicola Fiotti and Gabriele Grassi. **Cancer Investigation**, 2008 in press

34) Alcohol reduces mmp-2 in humans and isolated smooth muscle cells. Nicola Fiotti, Franco Tubaro, Gabriele Grassi, Michèle Moretti, Barbara Dapas, Rossella Farra, Nicola Altamura, Stefano Buiatti, Carlo Giansante. **Alcohol**, 2008 in press

### **Comunicazioni a congressi**

1) L. Zentilin, S. Tafuro, G. Grassi, S. Diviacco, M. Giacca A. Falaschi.

Malattia Granulomatosa Cronica: caratterizzazione molecolare e prospettive di trasferimento genico  
Atti XXX Convegno Società Italiana di Biofisica e Biologia Molecolare, Gubbio (PG) 4-6 ottobre 1993, pg. 59-60.

2) L. Zentilin, S. Tafuro, G. Grassi, A. Ventura, A. Falaschi, M. Giacca.

Terapia genica della Malattia Granulomatosa Cronica Mediante vettori retrovirali.

Atti Convegno Congiunto Associazione di Biologia Cellulare e del Differenziamento, Associazione Genetica Italiana, Società Italiana Biofisica e Biologia Molecolare, Società Italiana di Microbiologia Generale e Biotecnologie Microbiche., 26-30 Settembre 1994, Montesilvano Lido (Pescara)

3) M. Giacca, L. Zentilin, G. Grassi, S. Tafuro, A. Ventura, A. Falaschi.

Development of a competitive RT-PCR assay for the quantitative detection of gp91 gene expression in patients with chronic granulomatous disease.

Keystone Symposia on Molecular & Cellular Biology, Journal of Cellular Biochemistry, Supplement 18A, 1994, pg.237.

4) L. Zentilin, S. Tafuro, G. Grassi, A. Falaschi, M. Giacca.

Terapia genica della Malattia Granulomatosa Cronica Mediante vettori retrovirali.

Società Italiana di Ematologia Sperimentale. III Congresso Nazionale Udine-Grado 22-24 settembre 1994.

5) L. Zentilin, S. Tafuro, G. Grassi, A. Falaschi and M. Giacca.

Functional recostitution of the NADPH oxidase activity in B-lymphoblasts from patients with X-linked CGD by retrovirus-mediated gene transfer.

J. P. Lecoco Conference on Gene Therapy. Strasbourg 5-7 luglio 1994.

6) G. Grassi, M. Giacca, M. Moretti and G. Pozzato.

Competitive polymerase chain reaction for quantitative detection of HCV RNA in liver biopsies.

VI International Symposium on Viral Hepatitis. Madrid 3-5 febbraio 1994.

7) G. Grassi, G. Pozzato, M. Moretti e M. Giacca.

Quantificazione del genoma del virus dell'epatite C (HCV) in biopsie epatiche mediante RT-PCR competitive.

Atti Convegno Congiunto Associazione di Biologia Cellulare e del Differenziamento, Associazione Genetica Italiana, Società Italiana Biofisica e Biologia Molecolare, Società Italiana di Microbiologia Generale e Biotecnologie Microbiche., 26-30 Settembre 1994, Montesilvano Lido (Pescara)

8) G. Grassi, M. Giacca, M. Crovatto, G.F. Santini, M. Moretti, P. Marchi and G. Pozzato.

HCV-RNA quantitation in liver biopsy by competitive PCR: correlation with the HCV genotypes and with response to antiviral therapy.

EASL meeting. Atene 1994.

9) G. Grassi, B. Chiarotto, M. Crovatto, ML. Modolo, GF. Santini, M. Moretti, P. Marchi, P. Tulissi and G. Pozzato.

A new HCV genotype: typical of Italy?

The Italian Journal of Gastroenterology; 1994 Spring Meeting, Roma 9-10 June 1994.

10) G. Grassi, M. Giacca, P. Marchi, L. Mazzoran, E. Pussini and G. Pozzato.

HCV-RNA Quantitation in serum and liver biopsy by competitive PCR:

correlation with severity of the liver disease and with the response to antiviral therapy.

Journal of Hepatology, Supplement No. Vol. 23. 1995; Postgraduate Course and Abstracts of the 30th Annual Meeting of the European Association for the Study of the Liver, Copenaghen 20-23 August 1995.

11) G. Grassi and Joan C. Marini.

Allele-specific *in vitro* cleavage of collagen mRNA from Osteogenesis Imperfecta patients by hammerhead ribozymes.

16th Annual Meeting of the East Coast Connective Tissue Society - 22/23 March 1996, New York.

12) G.Grassi and Joan C. Marini

Hammerhead ribozymes achieve allele-specific cleavage of collagen mRNA *in vitro* from patients affected by Osteogenesis Imperfecta

Pediatric Academic Societies' Annual Meetings in Washington, D.C. - May 6-10, 1996.

13) G.Grassi and Joan C. Marini

Hammerhead ribozymes achieve allele-specific cleavage of collagen mRNA *in vitro* from patients affected by Osteogenesis Imperfecta

Sixth International Conference on the Molecular Biology and Pathology of Matrix. June 16-19, 1996 Philadelphia.

14) G.Grassi and Joan C. Marini

*In vitro* allele-specific cleavage of collagen mRNA from patients affected by Osteogenesis Imperfecta by hammerhead ribozymes: qualitative and quantitative analysis.

Gene therapy of Cancer, AIDS and Genetic Disorders. Trieste, April 10-13, 1996

15) A. Forlino, F. D. Porter, G. Grassi and J.C. Marini

Use of the cre/lox recombination system and site specific mutagenesis to target the COL1A1 gene: a strategy for generating a murine model of non-lethal Osteogenesis Imperfecta.

Sixth International Conference on Osteogenesis Imperfecta, Utrecht, September19-21, 1996

16) G.Grassi and Joan C. Marini

*In vitro* allele-specific cleavage of collagen mRNA from patients affected by Osteogenesis Imperfecta by hammerhead ribozymes: qualitative and quantitative analysis.

Sixth International Conference on Osteogenesis Imperfecta, Utrecht, September19-21, 1996

17) Dawson PA, Grassi G, Marini JC. Suppression of mutant type I collagen mRNA by hammehead ribozymes in cultured skin fibroblasts. American Journal of Human genetics 61 (4): 2076 Suppl. S

OCT 1997

18) Growth Inhibition Of Smooth Muscle Cells From Human Coronary Plaque Tissues By Hammerhead Ribozymes

Grassi, G., Kuhn, A., Bauriedel, G.2 and Kandolf, R. Kassel, 2-6 June 1998; Pathol Res Parct 194:267. 82. Jahrestagung der Gesellschaft für Pathologie

19) G. Grassi, A Kuhn, M. Grassi, G. Bauriedel, and R Kandolf  
Growth inhibition of smooth muscle cells from human coronary plaque tissue by hammerhead ribozymes. Fourth Cold Spring Harbor Meeting on Gene Therapy.  
Cold Spring Harbor, NY, September 23-27, 1998

20) A. Kuhn, G. Grassi, C. Teutsch, H. Köhn, D. Zell, G. Bauriedel, R. Kandolf.  
Gene therapeutic strategies to prevent human restenosis by induction of growth inhibition of smooth muscle cells. 83. Pathology Research and Practice, 195 (1999) 5 pp274; 83. Jahrestagung der Gesellschaft für Pathologie, Jena, May 26-29 1999

21) G. Grassi, A. Kuhn, J.J. Schnorr, H. Koehn, M. Grassi, G. Bauriedel, P. Di Nardo, R. Kandolf.  
Ribozymes as a tool to inhibit artery smooth muscle cell proliferation following percutaneous transluminal angioplasty.  
International meeting on "Dietary Factors and Cardiovascular Disease", 20-23 June 1999, Viterbo, Italy.

22) M. Grassi, G. Grassi, R. Lapasin, A.Kuhn, R. Kandolf  
Modeling of the in vitro hammerhead ribozyme reaction kinetics. The 26<sup>th</sup> International release of Bioctive Materials. Boston, June 20-25, 1999

23) G. Grassi, A Kuhn, JJ Schnor, H Koehn, M. Grassi, G. Bauriedel, and R Kandolf  
E2F1 and cyclin E directed ribozymes as a tool to inhibit smooth muscle cell proliferation after percutaneous transluminal angioplasty  
**European Heart Journal** 20 ISSN 0195 668X, 1999

24) G. Grassi, A. Kuhn, M. Grassi, G. Bauriedel, P., R. Kandolf.  
Ribozymes as a tool to inhibit smooth muscle cell proliferation.  
Drug delivery for the third millenium, Pisa, Italy October 10-12 1999

25) A. Kuhn, C. Teutsch, G. Petersen, G. Grassi., S. Knackmuss, E. Pfaff and R. Kandolf.  
Gene therapy strategies to prevent restenosis: identificantion of proteins that interact with and activate the growth arrest of homeobox protein gax.  
The Journal of Gene Medicine, Supplement to Vol 1 No 6, 1999. Seventh Meeting of the European Society of Gene Therapy, November 26-28, 1999, Munich, Germany.

26) G. Grassi, M. Grassi, R. Lapasin, A. Kuhn, R. Kandolf  
Calculation of cleavage kinetic constants for ribozyme carrying non hybridizing extra sequences.  
The 27<sup>th</sup> International Release of Bioactive Materials. Paris, July , 2000

27) G. Grassi, R. Kandolf and A. Kuhn  
Experimental Development of Concepts for the treatment of accelerated human atherosclerosis based on molecular genetic modulation of endogenous gene activity.  
Berlin, December 2000

28) G. Grassi, N. Cocceani, A. Kuhn, R. Kandolf, M. Grassi, R. Lapasin  
DNA Release From PLGA Microparticles

The 28<sup>th</sup> International Symposium on Release of Bioactive Materials. Proceed. Int'l Symp. Control.Rel.Bioact. Mater, 28 (2001).

29) G. Grassi, R. Kandolf, M. Grassi, G. Bauriedel, A. Kuhn

Phosphorothioate-modified ribozymes as tool to prevent restenosis

9<sup>th</sup> Meeting of the European Society of gene Therapy, Antalya, Turkey, November 2-4, 2001

30) Di Nardo P., Forte G., Grassi G., Kuhn A., Küpper H., Wolburg H., Minieri M., Fiaccavento R., carotenuto F., Fantini C., and Kandolf R.

Isolated cardiomyocyte grafting into cardiomyopathic hearts

Comitato Telethon Fondazione Onlus, Scientific convention, November 18-20 2001, Riva del Garda, Italy

31) G. Grassi, A. Schneider, A. Kuhn, , G. Bauriedel, R. Kandolf

Phosphorothioate-modified ribozymes directed against cyclin E and E2F1 mRNAs as tool to prevent restenosis. 68 Jahrestagung der Deutschen Gesellschaft für Kardiologie, 04-06 April 2002, Mannheim

32) M.Grassi, G. Grassi, A. Kuhn, R Kandolf, R. Lapasin

Modeling of ribozyme kinetics in presence of alternate ribozyme, substrate and activated complex configurations. 5th Conference on Mathematical Modelling & Computing in Biology and Medicine, Milano, 2-6 Luglio 2002.

33) G. Grassi, J. Platz, H. Köhn, S. Enge, A. Kuhn, C. Herdeg, R. Kandolf

Superiority of baculoviral vectors compared to adenoviral vectors in effective gene transfer for cardiovascular indications. European Society of Gene Therapy, 11<sup>th</sup> Annual Congress, Edinburgh, UK, November 14-17, 2003

34) siRNAs Targeting Serum Response Factor As Potential Tools To Interfere With In-Stent Restenosis. D Werth, O Heidenreich, A Nordheim, C Herdeg, G Grassi. European Society of Gene Therapy, 12<sup>th</sup> Annual Congress, Tampere, Finland, November 4-7, 2004

35) Small Interfering RNAs Targeting Serum Response Factor as Potential Tools to Interfere With In-Stent Restenosis. Christian Herdeg, Daniela Werth, O. Heidenreich, A. Nordheim, Gabriele Grassi, American College of Cardiology Meeting, Orlando, USA, March 2005.

36) Pluronic gel matrices for stent coating. A. Crevatin, R. Farra, G. Grassi, M. Grassi, R. Lapasin. 2nd Annual European Rheology Conference April 21-23, 2005  
Grenoble - France

37) Characterization of liposomes for the delivery of siRNAs in the treatment of coronary restenosis. Farra R, Voinovich D, Rubessa F, Lapasin R, Grassi M, Guarnieri G, Pascotto A, Rehimers B, Grassi G. European Journal of Pharmaceutical Sciences 25S1 (2005) xi–xv, page S 96.

38) siRNAs targeted against cyclin E1 and E2F1 down regulate coronary smooth muscle cell proliferation, thus showing their potential use in the prevention of in-stent restenosis. Dapas B., Farra R., Agostini F., Guarnieri G., Rainaldi G., Mercatanti A., Pascotto A., Rehimers B., and Grassi G. European Society of Gene Therapy, 13<sup>th</sup> Annual Congress, Praga, Rep Ceca, 31 Ottobre-2 November , 2005.

- 39) siRNAs targeted against coxsackieviruses B3 genome down regulate virus proliferation thus showing their potential use in the prevention of viral myocarditis Racchi G., Klingel K., Kandolf R., Rainaldi G., Mercatanti A., and Grassi G. European Society of Gene Therapy, 13<sup>th</sup> Annual Congress, Praga, Rep Ceca, 31 Ottobre-2 November , 2005.
- 40) Fenofibrate reduces apoptosis in endothelial cells in hyperglycemia. Stocca A., Grassi G., Dapas B., Farra R., Tedesco F., Cattin L., Guarnieri G., Zanetti M. XIX congresso Nazionale della Società Italiana per lo studio dell'Arteriosclerosi, Venezia Mestre, 23/26 Novembre 2005-11-2005
- 41) A siRNA targeted against SRF reduce hepatocellular carcinoma cell proliferation, showing its potential use in the growth inhibition of this type of tumor  
Farra R., Pozzato G., Dapas B., Agostini F., Scaggiante B., Guarnieri G., Colombo M., and Grassi G. The European Society for the study of the liver, Wien Austria, 26-30 April 2006
- 42) Rheological and mechanical properties of pluronic-alginate gels for drug-eluting stent coating  
G. Grassi, E. Noro, R. Farra, G. Guarnieri, R. Lapasin, M. Grassi, P. Matricardi, T. Coviello, A. DalCortivo and F. Alhaique. 9th European symposium on Controlled Drug Delivery, Twente, Netherlands, 2006; published in the special (online) issue of the Journal of Controlled Release, 2006
- 43) Proprietà reologiche di sistemi termoreversibili pluronico/arginato per applicazioni di stent coating  
A. Crevatin, E. Noro, G. Grassi, M. Grassi, R. Lapasin. Atti del IX convegno della Società Italiana di Reologia; Zambrone (VV) 20-23 Settembre 2006
- 44) Cyclin E1, E2 and E2F1 targeted siRNAs down regulate the growth of coronary smooth muscle cell, thus showing their potential use in the prevention of in-stent restenosis. Dapas B., Farra R., Giansante C, Guarnieri G., Rainaldi G., Mercatanti A., Pascotto A., Rehimers B., and Grassi G. Ireland Society of Gene and Cell Therapy Conference, Galway, 18 May 2007.
- 45) G. Grassi M. Grassi G. Pontrelli L. Teresi. A numerical study of a double layer gel paving technology in drug-eluting stent. Short Communication of the International Conference on Computational Biomechanics and Biology, Plzeň, Czech Republic University of West Bohemia, September 10–13, 2007.
- 46) M. Grassi, L. Davia, R. Lapasin, D. Voinovich, G. Pontrelli, G. Grassi. “Drug release from gel-stent systems: mathematical modeling”. First Conference on Innovation in drug delivery from biomaterial to devices. Naples, Italy, 30-9-07/3-10-07.
- 47) K. Klingel, C. Lang, G. Szalay, M. Sauter, G. Racchi, G. Grassi, G. Rainaldi, A. Mercatanti, F. Lang, R. Kandolf . “Cardiac fibrosis in enterovirus-induced myocarditis is mediated by connective tissue growth factor”. The European Society of Cardiology Congress , Messe Wien, September 2007, Austria.
- 48) P. Guiotto, K. Woelkart, G. Grassi, B. Campisi, B. Perissutti, R. Bauer, D. Voinovich. “Pharmacokinetic evaluation of phytotherapeutic drops with *E. purpurea* extract”. 55th International Congress & Annual Meeting of the Society for Medicinal Plant Research. Gesellschaft für Arzneipflanzenforschung – GAGRAZ, AUSTRIA September 2 – 6, 2007
- 49) Baiz D. , Pozzato G., Farra R., Dapas B., Scaggiante B. , Guarnieri G. and Grassi G. “Potential Application Of Proteasome Inhibitor Bortezomib For Treatment Of Hepatocellular Carcinoma”. Hong Kong – Shanghai International Liver Congress 12-15-June 2008

50) R.Farra, B.Dapas,D.Baiz, G.Pozzato, B. Scaggiante, G. Guarnieri and G.Grassi “SiRNAs targeted against cyclin E1, cyclin E2 and E2F1 down regulate the growth of Hepatocellular Carcinoma showing their potential use in the prevention of this type of tumor”. Hong Kong – Shanghai International Liver Congress 12-15-June 2008

51) L. Comel, A. Crevatin, G.Grassi, R. Lapsin, M. Grassi . “Studio della fluidodinamica coronarica in presenza di rivestimento interno atto al rilascio di agenti antiproliferativi” X Congresso Italiano di Reologia, Ravenna 18-21 Maggio 2008

52) Andrea Crevatin , Luigi Feruglio , Danilo Perin, Gabriele Grassi, Romano Lapsin, Mario Grassi “Gel di alginato-pluronic per il rilascio di agenti antiproliferativi”. G.R.I.C.U. 14-17 September 2008, Le Castella (KR), Italy

53) G. Cavallaro, M. Licciardi, G. Giammona, G. Grassi, B. Dapas, M. Grassi. “Impiego di vettori policationici a base poliamminoacidica per la veicolazione di sirna nel trattamento della in stent restenosi”. G.R.I.C.U. 14-17 September 2008, Le Castella (KR), Italy

### **Libri/capitoli**

1) Nell’ambito della collana “L’ambiente metabolico tra gene e malattia” Ed. Accademia Nazionale di Medicina, volume : “Cardiologia molecolare: nuove frontiere diagnostiche e terapeutiche”, capitolo: “La terapia genica per la prevenzione della restenosi vascolare”, Novembre, 2004

2) Per conto della casa editrice CRC (Boca Raton, Florida, USA) è co-autore di un libro dal titolo “Understanding drug release and absorption mechanisms: physical and mathematical approach”. Dicembre 2006.

3) Per il C.N.R. è co- autore (M. Grassi, G. Grassi, G. Pontrelli, L. Teresi) del capitolo 7: “Modelling drug release in cardiovascular eluting stents” nel contesto del libro: “Modelling Cardiovascular System & Mechanical Circulatory Support” Edito da Claudio De Lazzari. 2007.

4) Per conto della casa editrice Springer è co- autore (G. Grassi and M. Grassi) del capitolo: “Characterization Of Hammerhead Ribozymes Potentially Suitable For The Treatment Of Hyper-Proliferative Vascular Diseases” nel contesto del libro: “RNA Technologies in Cardiovascular Medicine and Research. Status and Challenges”. Volker A. Erdmann, Wolfgang Poller, Jan Barciszewski Editors. 2008 in pres.

### **Brevetti**

Domanda di brevetto per invenzione industriale in Italia n. MI2005A001982, dal titolo "Uso di small interfering RNA (SIRNA) per il trattamento di patologie caratterizzate da iperproliferazione cellulare", depositata in data 19 ottobre 2005